Issue 8/2026
Doychinova1, Ts., Naydenova2, Tsv, Yanchev2, D.
1 Infectious Diseases Clinic at University Hospital “Dr. G. Stranski” – Pleven
2 Medical University – Pleven
Lyme disease is an infectious disease that develops following a tick bite from a tick infected with bacteria of the genus Borrelia (Borrelia burgdorferi – Gram-negative spirochete). It appears that the general population has a compromised immune system, which is why Lyme disease is becoming more common. Standard treatment for Lyme disease involves antibiotics from the tetracycline and azithromycin groups; however, some patients exhibit a persistent active infection with Borrelia burgdorferi, which is most likely due to immune dysregulation and antigenic residues. Therefore, overcoming immune dysregulation and inflammation is necessary for long-term control of the disease. Imuflam has earned trust in the treatment of COVID-19. The present observation demonstrates a favorable trend in the use of Imuflam for Lyme disease as well. Imuflam provides a solution to key aspects of the prognosis and recovery from borreliosis.
Key words: Lyme disease, immune dysregulation, inflammation, Imuflam
Adress for correspondence:
Prof. Dr. Ts. Doychinova
Head of Infectious Diseases Clinic,
MHAT “Dr. G. Stranski” – Pleven
8А, „Georgi Kochev“, Str.
5809, Pleven
e-mail: doichinova_ceca@abv.bg